Form 8-K - Current report:
SEC Accession No. 0001193125-26-077416
Filing Date
2026-02-26
Accepted
2026-02-26 17:20:20
Documents
16
Period of Report
2026-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d85338d8k.htm   iXBRL 8-K 28832
2 EX-1.1 d85338dex11.htm EX-1.1 198475
3 EX-5.1 d85338dex51.htm EX-5.1 8293
7 GRAPHIC g85338dsp044.jpg GRAPHIC 11356
8 GRAPHIC g85338dsp44a.jpg GRAPHIC 14569
  Complete submission text file 0001193125-26-077416.txt   442642

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vir-20260225.xsd EX-101.SCH 2834
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vir-20260225_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vir-20260225_pre.xml EX-101.PRE 11251
18 EXTRACTED XBRL INSTANCE DOCUMENT d85338d8k_htm.xml XML 3630
Mailing Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158
Business Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Filer) CIK: 0001706431 (see all company filings)

EIN.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39083 | Film No.: 26690589
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)